Ixabepilone

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

Retrieved on: 
Thursday, December 1, 2022
Ovarian cancer, Cisplatin, COVID-19, Annual, Glioblastoma, RNA, Therapy, Cancer, Ixabepilone, Trial of the century, Clinical trial, Doxorubicin, Literature, Allare Allari, NDA, GBM, Security (finance), Patient, Partnership, PARP, Risk, PMA, Pharmaceutical industry

Boston, MA U.S.A. (December 1, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that the Companys adjourned 2022 Annual Stockholders Meeting (2022 ASM) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (2023 ASM) will be held, as a virtual meeting, on January 19, 2023.

Key Points: 
  • Boston, MA U.S.A. (December 1, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that the Companys adjourned 2022 Annual Stockholders Meeting (2022 ASM) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (2023 ASM) will be held, as a virtual meeting, on January 19, 2023.
  • The annual meeting was rescheduled to January 19, 2023 in light of the new proposals to be considered at the annual meeting.
  • Stockholders of record as of December 6, 2022, will be entitled to notice of, and to vote at, the 2023 ASM.
  • The Company, however, reserves the right to change the record date prior to the 2023 ASM.

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022
D, PARP, Literature, Research and development, RNA, Administration, G&A, R, Partnership, Therapy, Patient, Doxorubicin, Research, Public expenditure, Ixabepilone, Cisplatin, GBM, Glioblastoma, Cancer, Allar, Jerusalem, Ovarian cancer, Clinical trial, Pharmaceutical industry, Cryptocurrency

Cambridge, MA U.S.A. (November 15, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Cambridge, MA U.S.A. (November 15, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022.
  • Balance Sheet: As of September 30, 2022, Allaritys cash was $3.9 million, as compared to $19.6 million as of December 31, 2021.
  • Net Loss: Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

Retrieved on: 
Monday, November 7, 2022
Doxorubicin, Eastern Time Zone, Annual general meeting, Nasdaq, Partnership, Literature, Annual Meetings of the International Monetary Fund and the World Bank Group, PARP, GBM, The Meeting, Therapy, SEC, Ixabepilone, RNA, Proxy, U.S. Securities and Exchange Commission, Glioblastoma, Proxy statement, Company, Cancer, Proxy card, Clinical trial, Ovarian cancer, Patient, Allar Jõks, Cisplatin, Pharmaceutical industry, Holding company, Shareholder

Cambridge, MA U.S.A. (November 7, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today announced that the Companys 2022 Annual Meeting of Stockholders (the Meeting), was convened on November 4, 2022, at 1:00 p.m. (Eastern Time) and was adjourned without any business being conducted.

Key Points: 
  • Cambridge, MA U.S.A. (November 7, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care today announced that the Companys 2022 Annual Meeting of Stockholders (the Meeting), was convened on November 4, 2022, at 1:00 p.m. (Eastern Time) and was adjourned without any business being conducted.
  • The record date for the Annual Meeting remains the same, September 15, 2022.
  • Stockholders of record may attend the virtual webcast meeting on Friday, December 2, 2022, 1:00 p.m. (Eastern Time) by logging in through the same method.
  • Allarity encourages all stockholders, as of the record date on September 15, 2022, who have not yet voted to do so promptly.

EQS-News: Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

Retrieved on: 
Saturday, October 22, 2022
GBM, PARP, EGFR, Therapy, MYGN, Science, NRAS, Food and Drug Administration, Novartis, NYSE, NASDAQ, Neoplasm, Allar, Jerusalem, Patient, Drug development, Doxorubicin, Foundation Medicine, Research, Ixabepilone, Nasdaq, KRAS, Cancer, Food, Partnership, Company, Colorectal cancer, Safety, Advertising, Cisplatin, Association for Molecular Pathology v. Myriad Genetics, Inc., NVS, FDA, Gene, Ovarian cancer, Biomarker, Glioblastoma, Pharmaceutical industry, Medical imaging, Vaccine

Once brought into its pipeline , Allarity uses its DRP platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach.

Key Points: 
  • Once brought into its pipeline , Allarity uses its DRP platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach.
  • Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.
  • Allaritys Drug Response Predictor (DRP) platform is a unique bioanalytical platform that can create drug-specific predictive diagnostics for a wide range of cancer treatments.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

Retrieved on: 
Tuesday, October 11, 2022
Finance, Therapy, Administration, Ixabepilone, D, Intangible asset, University, R, CEO, Cancer, GBM, LLC, Research and development, Senior, Private Securities Litigation Reform Act, Jacobs School of Medicine and Biomedical Sciences, Company, Department, Osteosarcoma, Clinical trial, Literature, FDA, Society for Integrative Oncology, G&A, Risk, Division, Security (finance), Trial of the century, Board, Dean (education), CPA, U.S. Securities and Exchange Commission, Wolf, Ovarian cancer, Compliance, University at Buffalo, PARP, Department of Medicine – University of Pamplona, Patient, Biotechnology, Doxorubicin, Professor, RNA, Partnership, Nasdaq, Biomedical sciences, Research, Cisplatin, Forward-looking statement, COVID-19, Glioblastoma, Pharmaceutical industry, Online gambling, Management, Medicine, Allare Allari

On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022.

Key Points: 
  • On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022.
  • With this filing, the Company has addressed the cause of the non-compliant status with Nasdaq Listing Rule 5250(c)(1), as previously announced on August 26, 2022 .
  • On October 10, 2022, Nasdaq provided confirmation that upon the filing of the Companys Form 10-Q has regained compliance with Nasdaq Listing Rule 5250(c)(1) and the matter is now closed.
  • "We are very pleased to have completed the necessary Q2 filings and to have regained compliance with Nasdaqs listing requirements, said James G. Cullem, Chief Executive Officer at Allarity.

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

Retrieved on: 
Monday, September 26, 2022
Allare Allari, Therapy, Trial of the century, COVID-19, Director, Risk, Glioblastoma, Literature, LLC, Villanova University, Ovarian cancer, Company, GBM, Private Securities Litigation Reform Act, Cisplatin, Partnership, Ixabepilone, Forward-looking statement, Patient, Clinical trial, Cancer, U.S. Securities and Exchange Commission, Doxorubicin, CEO, MBA, Nasdaq, Board of directors, Neos, PARP, Drug development, Board, RNA, Merck & Co., Biotechnology, Security (finance), Merck, Pharmaceutical industry

Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management.

Key Points: 
  • Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management.
  • I am delighted that Jerry has chosen to join Allaritys board at this crucial time in our evolution, said Dr. Duncan Moore, Allaritys Chairman of the Board.
  • Prior to serving in this role, he was President, CEO, and Member of the Board of Directors at Neos Therapeutics (acquired by Aytu BioScience.)
  • Before joining Neos Therapeutics, he served as President, CEO, and Member of the Board of Directors at AgeneBio, Inc.

Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Friday, September 16, 2022
Allare Allari, Therapy, Trial of the century, COVID-19, Risk, Glioblastoma, Literature, Ovarian cancer, Company, Compliance, GBM, Private Securities Litigation Reform Act, Cisplatin, Partnership, Track, Ixabepilone, Forward-looking statement, Patient, Clinical trial, File, Cancer, U.S. Securities and Exchange Commission, Doxorubicin, Nasdaq, PARP, Form 10-Q, Form, RNA, Security (finance), Conference, Ladenburg Thalmann, SEC, Webcast, Pharmaceutical industry

Cambridge, MA U.S.A. (September 16, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1x1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY.

Key Points: 
  • Cambridge, MA U.S.A. (September 16, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1x1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY.
  • Investors interested in meeting with Allarity Therapeutics should contact their Ladenburg Thalmann representative or email the Company at [email protected].
  • In addition, the webcast will be available on the investor section of the Allarity website, and will be archived for 30 days following the conference.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Announces Appointment of New Auditor

Retrieved on: 
Monday, September 12, 2022
Therapy, Trial of the century, COVID-19, Wolf, Director, Risk, Glioblastoma, Literature, Ovarian cancer, Company, Compliance, GBM, Private Securities Litigation Reform Act, Cisplatin, Partnership, Ixabepilone, Forward-looking statement, Patient, Clinical trial, File, Cancer, U.S. Securities and Exchange Commission, Doxorubicin, P.C, Compte rendu, PARP, Form 10-Q, Board, Form, RNA, Security (finance), SEC, Pharmaceutical industry, Allare Allari, Nasdaq

Cambridge, MA U.S.A. (September 12, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C.

Key Points: 
  • Cambridge, MA U.S.A. (September 12, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C.
  • The appointment of Wolf & Company has been approved by both the audit committee and the Board of Directors (the Board) of the Company.
  • The appointment of Wolf & Company has no immediate effect on the Companys status as being non-compliant with Nasdaq Listing Rule 5250(c)(1).
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Retrieved on: 
Friday, August 26, 2022
Literature, Partnership, Security (finance), COVID-19, U.S. Securities and Exchange Commission, Allare Allari, RNA, Cancer, GBM, Therapy, File, Calendar, Doxorubicin, Letter, Forward-looking statement, SEC, Cisplatin, PARP, Form 10-Q, Company, Compliance, Glioblastoma, Ixabepilone, Form, Risk, Clinical trial, Ovarian cancer, Private Securities Litigation Reform Act, Trial of the century, Patient, Pharmaceutical industry, Nasdaq

This notification has no immediate effect on the listing of the Companys common stock on the Nasdaq.

Key Points: 
  • This notification has no immediate effect on the listing of the Companys common stock on the Nasdaq.
  • However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Companys common stock will be subject to delisting from Nasdaq.
  • Under the Nasdaq rules, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

Retrieved on: 
Tuesday, August 2, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Cisplatin, Time, Doxorubicin, Literature, MRCC, GBM, Type, U.S. Securities and Exchange Commission, Food, Ixabepilone, Trial of the century, Forward-looking statement, Fibroblast growth factor receptor, Partnership, Private Securities Litigation Reform Act, NDA, Risk, Board, Therapy, COVID-19, Coronavirus Scientific Advisory Board (Turkey), Cancer, Clinical trial, FDA, Company, Board of directors, Patient, Interim, Nasdaq, PARP, Security (finance), Â, Glioblastoma, Ovarian cancer, SAB, RNA, Pharmaceutical industry, Allare Allari

Cambridge, MA, U.S.A. (August 2, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Companys oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies.

Key Points: 
  • Cambridge, MA, U.S.A. (August 2, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Companys oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies.
  • Significantly broaden the Companys possibilities for future commercial partnering with larger pharmaceutical companies to maximize the value of its pipeline assets and DRP platform technology.
  • The Company is currently evaluating other potential Phase 1b/2 studies for either stenoparib or dovitinib combined with another oncology therapeutic, including the mRCC space.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.